TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.82
+5.19%Aug 31, 2026, 11:11 UTC
Heather Getz was appointed principal financial officer of TELA Bio, Inc., effective August 31, 2026.
Aug 31, 2026, 11:00 UTC
TELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles.
Source:Aug 31, 2026, 11:00 UTC
TELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.
Source:Aug 13, 2026, 00:00 UTC
TELA Bio, Inc. announced the departure of Chief Executive Officer Antony Koblish, effective August 3, 2026, with severance and equity acceleration terms disclosed in an 8-K filing.
Aug 10, 2026, 22:56 UTC
TELA Bio, Inc. reported a second-quarter loss of $0.20 per share, missing the Zacks Consensus Estimate of a $0.17 loss, and compared to a $0.22 loss a year earlier.
Source:Aug 4, 2026, 11:00 UTC
TELA Bio announced the appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026.